Table 2 Clinical and genetic characteristics of the glioblastoma study cohort.
Characteristic | Total cases (N = 75) | CCN1 high (N = 37) | CCN1 low (N = 38) |
|---|---|---|---|
Age - year | |||
Median | 60 | 66 | 56 |
Range | 19–81 | 25–76 | 19–81 |
Sex - no.(%) | |||
Male | 39 (52.0) | 21 (56.8) | 18 (47.4) |
Female | 36 (48.0) | 16 (43.2) | 20 (52.6) |
Surgical status – no.(%) | |||
Biopsy or partial resection | 41 (54.7) | 28 (75.7) | 13 (34.2) |
Gross total resection | 34 (35.3) | 9 (24.3) | 25 (65.8) |
Radiotherapy after 1st operation – no.(%) | |||
Standard radiotherapy | 68 (90.7) | 34 (91.9) | 34 (89.5) |
BNCT | 4 (5.3) | 1 (2.7) | 3 (7.9) |
None | 3 (4.0) | 2 (5.4) | 1 (2.6) |
Chemotherapy after 1st operation– no.(%) | |||
Temozolomide only | 63 (84.0) | 32 (86.5) | 31 (81.6) |
Temozolomide + others | 6 (8.0) | 3 (8.1) | 3 (7.9) |
Others | 4 (5.3) | 1 (2.7) | 3 (7.9) |
None | 2 (2.7) | 1 (2.7) | 1 (2.6) |
CCN1 expression– no.(%) | |||
High | 37 (49.3) | ||
Low | 38 (50.7) | ||
PIK3R1Met326Ile mutation – no.(%) | |||
Positive | 13 (17.3) | 10 (27.0) | 3 (7.9) |
Negative | 62 (82.7) | 27 (73.0) | 35 (92.1) |
